Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America

Clinical Infectious Diseases

Volumn 52, Issue 4, 2011, Pages

  Freifeld, Alison G ^a   Bow, Eric J ⁱ   Sepkowitz, Kent A ^b   Boeckh, Michael J ^d   Ito, James I ^e   Mullen, Craig A ^c   Raad, Issam I ^f   Rolston, Kenneth V ^f   Young, Jo Anne H ^g   Wingard, John R ^h  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f UNIVERSITY OF TEXAS   (United States)

^g UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF FLORIDA   (United States)

ⁱ UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMINOGLYCOSIDE; AMINOTRANSFERASE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BILIRUBIN; C REACTIVE PROTEIN; CARBAPENEM; CASPOFUNGIN; CEFEPIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CREATININE; FLUCONAZOLE; INTERLEUKIN 6; INTERLEUKIN 8; ITRACONAZOLE; LEVOFLOXACIN; MEROPENEM; MICAFUNGIN; PIPERACILLIN PLUS TAZOBACTAM; POSACONAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SIALIDASE INHIBITOR; UNINDEXED DRUG; VANCOMYCIN; VORICONAZOLE;

ABDOMINAL PAIN; ACINETOBACTER; ACUTE LEUKEMIA; ADENOVIRUS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPERGILLOSIS; BLOOD CELL COUNT; BLOOD CULTURE; CANCER CHEMOTHERAPY; CANDIDIASIS; CITROBACTER; COAGULASE NEGATIVE STAPHYLOCOCCUS; COMMON COLD; COUGHING; CREATININE BLOOD LEVEL; ENTEROBACTER; ESCHERICHIA COLI; EVIDENCE BASED PRACTICE; FEVER; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HERPES VIRUS; HIGH RISK PATIENT; HUMAN; HYPOTENSION; INFECTION; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; KLEBSIELLA; KLEBSIELLA PNEUMONIAE; LABORATORY TEST; LEUKEMIA; LEUKOCYTE COUNT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MYCOSIS; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; NEOPLASM; NEUTROPENIA; NEUTROPHIL COUNT; PARAINFLUENZA VIRUS INFECTION; PHYSICAL EXAMINATION; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RISK ASSESSMENT; RISK FACTOR; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; THORAX RADIOGRAPHY; THROMBOCYTE COUNT; UREA NITROGEN BLOOD LEVEL; VANCOMYCIN RESISTANT ENTEROCOCCUS;

EID: 79951816939     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir073     Document Type: Review

References (337)

1. Hughes WT, Arms (Pubitemid 34194843)
2. Klastersky J. Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis 2004;39(Suppl 1): S32-7. (Pubitemid 38971473)
3. Bodey GP, Buckley M, Sathe YS, et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-40.
4. Rosenberg PS, Alter BP, Bolyard AA, et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood 2006;107:4628-35. (Pubitemid 43882607)
5. Ramphal R. Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis 2004;39(Suppl 1): S25-31. (Pubitemid 38971472)
6. Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 1999;29:490-4. (Pubitemid 29439940)
7. Wisplinghoff H, Seifert H, Wenzel RP, et al. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003;36:1103-10. (Pubitemid 36553108)
8. Cattaneo C, Quaresmini G, Casari S, et al. Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution. J Antimicrob Chemother 2008;61:721-8. (Pubitemid 351321152)
9. Oliveira AL, de Souza M, Carvalho-Dias VM, et al. Epidemiology of bacteremia and factors associated with multi-drug-resistant gramnegative bacteremia in hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2007;39:775-81. (Pubitemid 46901976)
10. Chen CY, Tang JL, Hsueh PR, et al. Trends and antimicrobial resistance of pathogens causing bloodstream infections among febrile neutropenic adults with hematological malignancy. J Formos Med Assoc 2004;103:526-32.
11. Johnson MP, Ramphal R. Beta-lactam-resistant Enterobacter bacteremia in febrile neutropenic patients receiving monotherapy. J Infect Dis 1990;162:981-3. (Pubitemid 20336545)
12. Johnson PR, Liu Yin JA, Tooth JA. A randomized trial of high-dose ciprofloxacin versus azlocillin and netilmicin in the empirical therapy of febrile neutropenic patients. J Antimicrob Chemother 1992;30:203-14.
13. Aubron C, Poirel L, Fortineau N, et al. Nosocomial spread of Pseudomonas aeruginosa isolates expressing the metallo-beta-lactamase VIM-2 in a hematology unit of a French hospital. Microb Drug Resist 2005;11:254-9. (Pubitemid 41434170)
14. Morris PG, Hassan T, McNamara M, et al. Emergence of MRSA in positive blood cultures from patients with febrile neutropenia-a cause for concern. Support Care Cancer 2008;16:1085-8.
15. Weinstock DM, Conlon M, Iovino C, et al. Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant 2007;13:615-21. (Pubitemid 46585935)
16. Carratala J, Roson B, Fernandez-Sevilla A, et al. Bacteremic pneumonia in and neutropenic patients with cancer: causes, empirical antibiotic therapy, and outcome. Arch Intern Med 1998;158:868-72. (Pubitemid 28183641)
17. Zuckermann J, Moreira LB, Stoll P, et al. Compliance with a critical pathway for the management of febrile neutropenia and impact on clinical outcomes. Ann Hematol 2008;87:139-45.
18. Field MJ, Lohr KN. Institute of Medicine Committee to Advise the Public Health Service on Clinical Practice Guidelines, Clinical practice guidelines: directions for a new program. Washington, DC: National Academy Press, 1990;8.
19. Canadian Task Force on the Periodic Health Examination. The periodic health examination. Can Med Assoc J 1979;121:1193-254.
20. Gardembas-Pain M, Desablens B, Sensebe L, et al. Home treatment of febrile neutropenia: an empirical oral antibiotic regimen. Ann Oncol 1991;2:485-7.
21. Malik IA, Abbas Z, Karim M. Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet 1992;339:1092-6.
22. Aquino VM, Tkaczewski I, Buchanan GR. Early discharge of low-risk febrile neutropenic children and adolescents with cancer. Clin Infect Dis 1997;25:74-8. (Pubitemid 27293077)
23. Freifeld A, Marchigiani D, Walsh T, et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999;341:305-11. (Pubitemid 29350300)
24. Hidalgo M, Hornedo J, Lumbreras C, et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer 1999;85:213-9. (Pubitemid 29031377)
25. Jones GR, Konsler GK, Dunaway RP, et al. Risk factors for recurrent fever after the discontinuation of empiric antibiotic therapy for fever and neutropenia in pediatric patients with a malignancy or hematologic condition. J Pediatr 1994;124:703-8. (Pubitemid 24161457)
26. Kern WV, Cometta A, De Bock R, et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1999;341:312-8. (Pubitemid 29350301)
27. Klaassen RJ, Goodman TR, Pham B, et al. "Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol 2000;18:1012-9. (Pubitemid 30123777)
28. Malik IA, Khan WA, Karim M, et al. Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. Am J Med 1995;98:224-31.
29. Mullen CA, Petropoulos D, Roberts WM, et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer 1999;86:126-34. (Pubitemid 29293385)
30. Paganini HR, Sarkis CM, De Martino MG, et al. Oral administration of cefixime to lower risk febrile neutropenic children with cancer. Cancer 2000;88:2848-52. (Pubitemid 30417949)
31. Rackoff WR, Gonin R, Robinson C, et al. Predicting the risk of bacteremia in childen with fever and neutropenia. J Clin Oncol 1996;14:919-24. (Pubitemid 26085537)
32. Rolston KV. New trends in patient management: risk-based therapy for febrile patients with neutropenia. Clin Infect Dis 1999;29:515-21. (Pubitemid 29439944)
33. Shenep JL, Flynn PM, Baker DK, et al. Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer. Clin Infect Dis 2001;32:36-43. (Pubitemid 32150948)
34. Talcott JA, Siegel RD, Finberg R, et al. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 1992;10:316-22.
35. Elting LS, Lu C, Escalante CP, et al. Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol 2008;26:606-11. (Pubitemid 351264355)
36. Rolston KV, Manzullo EF, Elting LS, et al. Once daily, oral, outpatient quinolone monotherapy for low-risk cancer patients with fever and neutropenia: a pilot study of 40 patients based on validated riskprediction rules. Cancer 2006;106:2489-94. (Pubitemid 43787675)
37. Rubenstein EB, Rolston K, Benjamin RS, et al. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 1993;71:3640-6. (Pubitemid 23152677)
38. Velasco E, Costa MA, Martins CA, et al. Randomized trial comparing oral ciprofloxacin plus penicillin V with amikacin plus carbenicillin or ceftazidime for empirical treatment of febrile neutropenic cancer patients. Am J Clin Oncol 1995;18:429-35.
39. Petrilli AS, Dantas LS, Campos MC, et al. Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: randomized prospective trial. Med Pediatr Oncol 2000;34:87-91. (Pubitemid 30090470)
40. Innes HE, Smith DB, O'Reilly SM, et al. Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. Br J Cancer 2003;89:43-9. (Pubitemid 36897933)
41. Kamana M, Escalante C, Mullen CA, et al. Bacterial infections in lowrisk, febrile neutropenic patients. Cancer 2005;104:423-6.
42. Klastersky J, Paesmans M, Georgala A, et al. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 2006;24:4129-34. (Pubitemid 46622289)
43. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18:3038-51. (Pubitemid 30644129)
44. Klastersky J, Ameye L, Maertens J, et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents 2007;30(Suppl 1): S51-9.
45. Kern WV. Risk assessment and treatment of low-risk patients with febrile neutropenia. Clin Infect Dis 2006;42:533-40. (Pubitemid 43202527)
46. Talcott JA, Finberg R, Mayer RJ, et al. The medical course of cancer patients with fever neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 1988;148:2561-8. (Pubitemid 19048173)
47. Mermel LA, Maki DG. Detection of bacteremia in adults: consequences of culturing an inadequate volume of blood. Ann Intern Med 1993;119:270-2. (Pubitemid 23319882)
48. Gaur AH, Flynn PM, Heine DJ, et al. Diagnosis of catheter-related bloodstream infections among pediatric oncology patients lacking a peripheral culture, using differential time to detection. Pediatr Infect Dis J 2005;24:445-9. (Pubitemid 40664241)
49. Lee A, Mirrett S, Reller LB, et al. Detection of bloodstream infections in adults: how many blood cultures are needed? J Clin Microbiol 2007;45:3546-8. (Pubitemid 350156846)
50. Cockerill FR 3rd, Wilson JW, Vetter EA, et al. Optimal testing parameters for blood cultures. Clin Infect Dis 2004;38:1724-30. (Pubitemid 38781664)
51. DesJardin JA, Falagas ME, Ruthazer R, et al. Clinical utility of blood cultures drawn from indwelling central venous catheters in hospitalized patients with cancer. Ann Intern Med 1999;131:641-7. (Pubitemid 29517948)
52. Weinstein MP. Current blood culture methods and systems: clinical concepts, technology, and interpretation of results. Clin Infect Dis 1996;23:40-6. (Pubitemid 26323793)
53. Adamkiewicz TV, Lorenzana A, Doyle J, et al. Peripheral vs. central blood cultures in patients admitted to a pediatric oncology ward. Pediatr Infect Dis J 1999;18:556-8. (Pubitemid 29277625)
54. Allen U, Smith CR, Prober CG. The value of skin biopsies in febrile, neutropenic, immunocompromised children. Am J Dis Child 1986;140:459-61. (Pubitemid 16114740)
55. von Lilienfeld-Toal M, Dietrich MP, Glasmacher A, et al. Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein. Eur J Clin Microbiol Infect Dis 2004;23:539-44. (Pubitemid 39004102)
56. Persson L, Soderquist B, Engervall P, et al. Assessment of systemic inflammation markers to differentiate a stable from a deteriorating clinical course in patients with febrile neutropenia. Eur J Haematol 2005;74:297-303. (Pubitemid 40461149)
57. von Lilienfeld-Toal M, Schneider A, Orlopp K, et al. Change of procalcitonin predicts clinical outcome of febrile episodes in patients with hematological malignancies. Support Care Cancer 2006;14:1241-5. (Pubitemid 44810851)
58. Pizzo PA, Robichaud KJ, Gill FA, et al. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982;72:101-11. (Pubitemid 12090793)
59. Schimpff SC. Empiric antibiotic therapy for granulocytopenic cancer patients. Am J Med 1986;80:13-20. (Pubitemid 16090510)
60. Antoniadou A, Giamarellou H. Fever of unknown origin in febrile leukopenia. Infect Dis Clin North Am 2007;21:1055-90. (Pubitemid 350166841)
61. Spanik S, Krupova I, Trupl J, et al. Bacteremia due to multiresistant gram-negative bacilli in neutropenic cancer patients: a case-controlled study. J Infect Chemother 1999;5:180-84. (Pubitemid 29484867)
62. Falcone M, Micozzi A, Pompeo ME, et al. Methicillin-resistant staphylococcal bacteremia in patients with hematologic malignancies: clinical and microbiological retrospective comparative analysis of S. haemolyticus, S. epidermidis and S. aureus. J Chemother 2004;16:540-8.
63. Bow EJ, Rotstein C, Noskin GA, et al. A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin- tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. Clin Infect Dis 2006;43:447-59. (Pubitemid 44157153)
64. Glasmacher A, von Lilienfeld-Toal M, Schulte S, et al. An evidencebased evaluation of important aspects of empirical antibiotic therapy in febrile neutropenic patients. Clin Microbiol Infect 2005;11(Suppl 5): 17):17-23. (Pubitemid 41348481)
65. Cherif H, Bjorkholm M, Engervall P, et al. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies. Scand J Infect Dis 2004;36:593-600. (Pubitemid 39247980)
66. Escalante CP, Weiser MA, Manzullo E, et al. Outcomes of treatment pathways in outpatient treatment of low risk febrile neutropenic cancer patients. Support Care Cancer 2004;12:657-62. (Pubitemid 39280317)
67. Raad II, Escalante C, Hachem RY, et al. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime. Cancer 2003;98:1039-47. (Pubitemid 37022106)
68. Wang FD, Liu CY, Hsu HC, et al. A comparative study of cefepime versus ceftazidime as empiric therapy of febrile episodes in neutropenic patients. Chemotherapy 1999;45:370-9.
69. Biron P, Fuhrmann C, Cure H, et al. Cefepime versus imipenemcilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer). J Antimicrob Chemother 1998;42:511-8. (Pubitemid 28473012)
70. Freifeld AG, Walsh T, Marshall D, et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 1995;13:165-76.
71. Mustafa MM, Carlson L, Tkaczewski I, et al. Comparative study of cefepime versus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia. Pediatr Infect Dis J 2001;20:362-9. (Pubitemid 32240289)
72. Corapcioglu F, Sarper N, Zengin E. Monotherapy with piperacillin/ tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison. Pediatr Hematol Oncol 2006;23:177-86. (Pubitemid 43361800)
73. Oguz A, Karadeniz C, Citak EC, et al. Experience with cefepime versus meropenem as empiric monotherapy for neutropenia and fever in pediatric patients with solid tumors. Pediatr Hematol Oncol 2006;23:245-53. (Pubitemid 43361806)
74. Ramphal R. Is monotherapy for febrile neutropenia still a viable alternative? Clin Infect Dis 1999;29:508-14. (Pubitemid 29439943)
75. Raad II, Abi-Said D, Rolston KV, et al. How should imipenemcilastatin be used in the treatment of fever and infection in neutropenic cancer patients? Cancer 1998;82:2449-58. (Pubitemid 28283453)
76. Ramphal R, Gucalp R, Rotstein C, et al. Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient. Am J Med 1996;100:83S-89S.
77. Feld R, DePauw B, Berman S, et al. Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial. J Clin Oncol 2000;18:3690-8.
78. Owens RC, Owens CA, Holloway WJ. Reduction in vancomycin consumption in patients with fever and neutropenia. Clin Infect Dis 2000;31:291.
79. Vandercam B, Gerain J, Humblet Y, et al. Meropenem versus ceftazidime as empirical monotherapy for febrile neutropenic cancer patients. Ann Hematol 2000;79:152-7. (Pubitemid 30195613)
80. Rubinstein E, Lode H, Grassi C. Ceftazidime monotherapy vs. ceftriaxone/tobramycin for serious hospital-acquired gram-negative infections. Antibiotic Study Group. Clin Infect Dis 1995;20:1217-28.
81. Winston DJ, Ho WG, Bruckner DA, et al. Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann Intern Med 1991;115:849-59.
82. De Pauw BE, Deresinski SC, Feld R, et al. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group. Ann Intern Med 1994;120:834-44. (Pubitemid 24140509)
83. Pizzo PA, Hathorn JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986;315:552-8. (Pubitemid 16052468)
84. Lindblad R, Rodjer S, Adriansson M, et al. Empiric monotherapy for febrile neutropenia-a randomized study comparing meropenem with ceftazidime. Scand J Infect Dis 1998;30:237-43. (Pubitemid 28461591)
85. Behre G, Link H, Maschmeyer G, et al. Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients. Ann Hematol 1998;76:73-80. (Pubitemid 28118727)
86. Bohme A, Shah PM, Stille W, et al. Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study. Eur J Med Res 1998;3:324-30.
87. Del Favero A, Menichetti F, Martino P, et al. A multicenter, doubleblind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis 2001;33:1295-301. (Pubitemid 32955177)
88. Engervall P, Kalin M, Dornbusch K, et al. Cefepime as empirical monotherapy in febrile patients with hematological malignancies and neutropenia: a randomized, single-center phase II trial. J Chemother 1999;11:278-86. (Pubitemid 29382623)
89. Ozyilkan O, Yalcintas U, Baskan S. Imipenem-cilastatin versus sulbactam-cefoperazone plus amikacin in the initial treatment of febrile neutropenic cancer patients. Korean J Intern Med 1999;14:15-9.
90. Akova M, Akan H, Korten V, et al. Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: a prospective randomised multicentre trial in patients without previous prophylactic antibiotics. Meropenem Study Group of Turkey. Int J Antimicrob Agents 1999;13:15-9. (Pubitemid 29452995)
91. Yamamura D, Gucalp R, Carlisle P, et al. Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients. Antimicrob Agents Chemother 1997;41:1704-8. (Pubitemid 27339871)
92. Cometta A, Calandra T, Gaya H, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program. Antimicrob Agents Chemother 1996;40:1108-15.
93. Paul M, Soares-Weiser K, Grozinsky S, et al. Beta-lactam versus betalactam-aminoglycoside combination therapy in cancer patients with neutropaenia. Cochrane Database Syst Rev 2003: CD003038.
94. Paterson DL, Ko WC, Von Gottberg A, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001;39:2206-12. (Pubitemid 32531482)
95. Kang CI, Kim SH, Park WB, et al. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 2004;48:4574-81.
96. Fritsche TR, Sader HS, Jones RN. Comparative activity and spectrum of broad-spectrum beta-lactams (cefepime, ceftazidime, ceftriaxone, piperacillin/tazobactam) tested against 12, 295 staphylococci and streptococci: report from the SENTRY antimicrobial surveillance program (North America: 2001-2002). Diagn Microbiol Infect Dis 2003;47:435-40. (Pubitemid 38373417)
97. Yahav D, Paul M, Fraser A, et al. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis 2007;7:338-48. (Pubitemid 46591956)
98. Nguyen TD, Williams B, Trang E. Cefepime therapy all-cause mortality. Clin Infect Dis 2009;49:641-2.
99. Gomez L, Quintana S, Garau J. Mortality associated with cefepime therapy among neutropenic patients. Clin Infect Dis 2009;49:987.
100. Toye B, Krajden S, Fuksa M, et al. Carbapenem resistance in Canada. CMAJ 2009;180:1225-6.
101. Chemaly RF, Hanmod SS, Jiang Y, et al. Tigecycline use in cancer patients with serious infections: a report on 110 cases from a single institution. Medicine (Baltimore) 2009;88:211-20.
102. No authors listed. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group. J Infect Dis 1991;163:951-8.
103. Paul M, Borok S, Fraser A, et al. Empirical antibiotics against gram-positive infections for febrile neutropenia: systematic review and meta-zanalysis of randomized controlled trials. J Antimicrob Chemother 2005;55:436-44. (Pubitemid 40542581)
104. Elting LS, Rubenstein EB, Rolston KV, et al. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997;25:247-59. (Pubitemid 27364722)
105. Razonable RR, Litzow MR, Khaliq Y, et al. Bacteremia due to viridans group Streptococci with diminished susceptibility to levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. Clin Infect Dis 2002;34:1469-74. (Pubitemid 34553706)
106. Nucci M, Landau M, Silveira F, et al. Application of the IDSA guidelines for the use of antimicrobial agents in neutropenic patients: impact on reducing the use of glycopeptides. Infect Control Hosp Epidemiol 2001;22:651-3. (Pubitemid 33152111)
107. Mehta S, Johnson J, Venezia R, et al. Emergence of linezolidresistant enterococci in a neutropenic patient. J Hosp Infect 2006;62:125-7. (Pubitemid 43103028)
108. Verma N, Clarke RW, Bolton-Maggs PH, et al. Gut overgrowth of vancomycin-resistant enterococci (VRE) results in linezolid-resistant mutation in a child with severe congenital neutropenia: a case report. J Pediatr Hematol Oncol 2007;29:557-60. (Pubitemid 47356810)
109. Aksoy DY, Unal S. New antimicrobial agents for the treatment of gram-positive bacterial infections. Clin Microbiol Infect 2008;14:411-20. (Pubitemid 351513929)
110. Rice LB. Antimicrobial resistance in gram-positive bacteria. Am J Infect Control 2006;34: S11-9; discussion, S64-S73.
111. Whitener CJ, Park SY, Browne FA, et al. Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure. Clin Infect Dis 2004;38:1049-55. (Pubitemid 38951246)
112. Cunha BA. Antimicrobial therapy of multidrug-resistant Strptococcus pneumoniae, vancomycin-resistant enterococci, and methicillinresistant Staphylococcus aureus. Med Clin North Am 2006;90:1165-82. (Pubitemid 44751031)
113. Bruckner L, Gigliotti F. Viridans group streptococcal infections among children with cancer and the importance of emerging antibiotic resistance. Semin Pediatr Infect Dis 2006;17:153-60. (Pubitemid 44278618)
114. Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis 1992;14:1201-7.
115. Gruson D, Hilbert G, Pigneux A, et al. Severe infection caused by Stomatococcus mucilaginosus in a neutropenic patient: case report and review of the literature. Hematol Cell Ther 1998;40:167-9. (Pubitemid 28432316)
116. Kumashi P. Girgawy E. Tarrand JJ, et al. e bacteremia in patients with cancer: disease characteristics and outcomes in the era of escalating drug resistance (1998-2002). Medicine (Baltimore) 2005;84:303-312. (Pubitemid 41368483)
117. DiazGranados CA, Jernigan JA. Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection. J Infect Dis 2005;191:588-95. (Pubitemid 40216675)
118. Koc Y, Snydman DR, Schenkein DS, et al. Vancomycin-resistant enterococcal infections in bone marrow transplant recipients. Bone Marrow Transplant 1998;22:207-9. (Pubitemid 28375664)
119. Vergis EN, Hayden MK, Chow JW, et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. a prospective multicenter study. Ann Intern Med 2001;135:484-92. (Pubitemid 32923565)
120. Johnson PR, Yin JA, Tooth JA. High dose intravenous ciprofloxacin in febrile neutropenic patients. J Antimicrob Chemother 1990;26(Suppl F): 101-7.
121. Winston DJ, Lazarus HM, Beveridge RA, et al. Randomized, doubleblind, multicenter trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patients. Clin Infect Dis 2001;32:381-90. (Pubitemid 32173623)
122. Meunier F, Zinner SH, Gaya H, et al. Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. The European Organization for Research on Treatment of Cancer International Antimicrobial Therapy Cooperative Group. Antimicrob Agents Chemother 1991;35:873-8.
123. Anaissie EJ, Fainstein V, Bodey GP, et al. Randomized trial of betalactam regimens in febrile neutropenic cancer patients. Am J Med 1988;84:581-9.
124. Bodey GP, Fainstein V, Elting LS, et al. Beta-lactam regimens for the febrile neutropenic patient. Cancer 1990;65:9-16. (Pubitemid 20026802)
125. Freifeld A, Sankaranarayanan J, Ullrich F, et al. Clinical practice patterns of managing low-risk adult febrile neutropenia during cancer chemotherapy in the USA. Support Care Cancer 2008;16:181-91.
126. Cornely OA, Wicke T, Seifert H, et al. Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia. Int J Hematol 2004;79:74-8. (Pubitemid 38182205)
127. Burgess DS, Hall RG, Hardin TC. In vitro evaluation of the activity of two doses of levofloxacin alone and in combination with other agents against Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 2003;46:131-7. (Pubitemid 36703350)
128. Garrison MW. Pharmacodynamic assessment of the activity of highdose (750 mg) levofloxacin, ciprofloxacin, and gatifloxacin against clinical strains of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 2006;54:51-6. (Pubitemid 41815188)
129. Cometta A, Kern WV, De Bock R, et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis 2003;37:382-9. (Pubitemid 36976496)
130. Gil L, Styczynski J, Komarnicki M. Infectious complication in 314 patients after high-dose therapy and autologous hematopoietic stem cell transplantation: risk factors analysis and outcome. Infection 2007;35:421-7. (Pubitemid 350307984)
131. Wade JC, Glasmacher A. Vancomycin does not benefit persistently febrile
132. No authors listed. Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 1995;44:1-13.
133. Ligova A, Matuska M, Mrazkova P, et al. Clostridium difficile associated diarrhoea-problem of oncological patient? [in German]. Klin Onkol 2009;22:108-16.
134. Cloutier RL. Neutropenic enterocolitis. Emerg Med Clin North Am 2009;27:415-22.
135. Ullery BW, Pieracci FM, Rodney JR, et al. Neutropenic enterocolitis. Surg Infect (Larchmt) 2009;10:307-14.
136. Kang CI, Kim SH, Park WB, et al. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 2005;49:760-6.
137. Ibrahim EH, Sherman G, Ward S, et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000;118:146-55. (Pubitemid 30485502)
138. Lodise TP Jr., Patel N, Kwa A, et al. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother 2007;51:3510-5. (Pubitemid 47519337)
139. Paul M, Silbiger I, Grozinsky S, et al. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 2006: CD003344.
140. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in and gram-negative bacteraemia? A metaanalysis. Lancet Infect Dis 2004;4:519-7.
141. No authors listed. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
142. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000;31(Suppl 4): S131-8. (Pubitemid 32291120)
143. Jaksic B, Martinelli G, Perez-Oteyza J, et al. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis 2006;42:597-607. (Pubitemid 43271371)
144. Faguer S, Kamar N, Fillola G, et al. Linezolid-related pancytopenia in organ-transplant patients: report of two cases. Infection 2007;35:275-7. (Pubitemid 47222274)
145. Levy MJ, Norton ID, Clain JE, et al. Prospective study of bacteremia and complications with EUS FNA of rectal and perirectal lesions. Clin Gastroenterol Hepatol 2007;5:684-9. (Pubitemid 46830057)
146. Gorschluter M, Mey U, Strehl J, et al. Neutropenic enterocolitis in adults: systematic analysis of evidence quality. Eur J Haematol 2005;75:1-13. (Pubitemid 40873955)
147. Cronin CG, O'Connor M, Lohan DG, et al. Imaging of the gastrointestinal complications of systemic chemotherapy. Clin Radiol 2009;64:724-33.
148. Marra CA, Frighetto L, Quaia CB, et al. A new ciprofloxacin stepdown program in the treatment of high-risk febrile neutropenia: a clinical and economic analysis. Pharmacotherapy 2000;20:931-40. (Pubitemid 30659790)
149. Hodgson-Viden H, Grundy PE, Robinson JL. Early discontinuation of intravenous antimicrobial therapy in pediatric oncology patients with febrile neutropenia. BMC Pediatr 2005;5:10.
150. Lehrnbecher T, Stanescu A, Kuhl J. Short courses of intravenous empirical antibiotic treatment in selected febrile neutropenic children with cancer. Infection 2002;30:17-21. (Pubitemid 34146407)
151. Grazziutti ML, Dong L, Miceli MH, et al. Recovery from neutropenia can be predicted by the immature reticulocyte fraction several days before neutrophil recovery in autologous stem cell transplant recipients. Bone Marrow Transplant 2006;37:403-9. (Pubitemid 43250475)
152. Molina JR, Sanchez-Garcia J, Torres A, et al. Reticulocyte maturation parameters are reliable early predictors of hematopoietic engraftment after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2007;13:172-82. (Pubitemid 46112368)
153. Pizzo PA. Approach to the patient with prolonged granulocytopenia. Recent Results Cancer Res 1993;132:57-65.
154. Gill S, Carney D, Ritchie D, et al. The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy. Ann Oncol 2010;21:331-4.
155. Horowitz HW, Holmgren D, Seiter K. Stepdown single agent antibiotic therapy for the management of the high risk neutropenic adult with hematologic malignancies. Leuk Lymphoma 1996;23:159-63. (Pubitemid 26359956)
156. Bodey GP. The treatment of febrile neutropenia: from the Dark Ages to the present. Support Care Cancer 1997;5:351-7. (Pubitemid 27402586)
157. Bow EJ. Management of the febrile neutropenic cancer patient: lessons from 40 years of study. Clin Microbiol Infect 2005;11(Suppl 5): 24):24-9. (Pubitemid 41348482)
158. Cruciani M, Rampazzo R, Malena M, et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a metaanalysis. Clin Infect Dis 1996;23:795-805. (Pubitemid 26331127)
159. Cruciani M, Malena M, Bosco O, et al. Reappraisal with meta-analysis of the addition of gram-positive prophylaxis to fluoroquinolone in neutropenic patients. J Clin Oncol 2003;21:4127-37. (Pubitemid 46606180)
160. Rotstein C, Mandell LA, Goldberg N. Fluoroquinolone prophylaxis for profoundly neutropenic cancer patients: a meta-analysis. Opin Oncol 1997;4:2-7.
161. Gafter-Gvili A, Fraser A, Paul M, et al. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005;142:979-95. (Pubitemid 40840313)
162. Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 1998;16:1179-87. (Pubitemid 28108756)
163. van de Wetering MD, de Witte MA, Kremer LC, et al. Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: a systematic review of randomised controlled trials. Eur J Cancer 2005;41:1372-82. (Pubitemid 40826460)
164. Baden LR. Prophylactic antimicrobial agents and the importance of fitness. N Engl J Med 2005;353:1052-4. (Pubitemid 41262340)
165. van Belkum A, Vos MC. Prophylactic application of fluoroquinolones for selective decontamination of the gut: friend or foe. Eur J Clin Microbiol Infect Dis 2005;24:109-10. (Pubitemid 40487378)
166. Almyroudis NG, Segal BH. Antibacterial prophylaxis in patients with cancer and neutropenia. N Engl J Med 2006;354:90-4; author reply, 90-94.
167. Pasqualotto AC, Rosa DD, Machado AL. Antibacterial prophylaxis in patients with cancer and neutropenia. N Engl J Med 2006;354:90-4; author reply, 90-94.
168. Dykewicz CA. Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. Clin Infect Dis 2001;33:139-44. (Pubitemid 32643326)
169. Masaoka T. Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary. Clin Infect Dis 2004;39(Suppl 1): S49-52. (Pubitemid 38971476)
170. Santolaya ME, Rabagliati R, Bidart T, et al. Consensus: Rational approach towards the patient with cancer, fever and neutropenia [in Spanish]. Rev Chilena Infectol 2005;22(Suppl 2): S79-113.
171. Link H, Bohme A, Cornely OA, et al. Antimicrobial therapy of unexplained fever in neutropenic patients-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol 2003;82(Suppl 2): S105-17. (Pubitemid 37265297)
172. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009;15:1143-238.
173. Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005;353:977-87. (Pubitemid 41262332)
174. Cullen M, Steven N, Billingham L, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005;353:988-98. (Pubitemid 41262333)
175. Leibovici L, Paul M, Cullen M, et al. Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer 2006;107:1743-51. (Pubitemid 44582942)
176. Noel GJ, Bradley JS, Kauffman RE, et al. Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders. Pediatr Infect Dis J 2007;26:879-91. (Pubitemid 47494159)
177. Richard DA, Nousia-Arvanitakis S, Sollich V, et al. Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Cystic Fibrosis Study Group. Pediatr Infect Dis J 1997;16:572-8. (Pubitemid 27255757)
178. Hampel B, Hullmann R, Schmidt H. Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use-safety report. Pediatr Infect Dis J 1997;16:127-9; discussion, 60-62. (Pubitemid 27063131)
179. Reuter S, Kern WV, Sigge A, et al. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. Clin Infect Dis 2005;40:1087-93. (Pubitemid 40490230)
180. Ito JI, Tegtmeier BR, O'Donnell MR. Antibacterial prophylaxis in patients with cancer and neutropenia. N Engl J Med 2006;354:90-4; author reply, 90-94.
181. Kern WV, Klose K, Jellen-Ritter AS, et al. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis 2005;24:111-8. (Pubitemid 40487379)
182. Gomez L, Garau J, Estrada C, et al. Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with a high prevalence of ciprofloxacin and resistant Escherichia coli. Cancer 2003;97:419-24. (Pubitemid 36133809)
183. Martino R, Subira M, Altes A, et al. Effect of discontinuing prophylaxis with norfloxacin in patients with hematologic malignancies and severe neutropenia. A matched case-control study of the effect on infectious morbidity. Acta Haematol 1998;99:206-11. (Pubitemid 28230389)
184. Gasink LB, Fishman NO, Weiner MG, et al. Fluoroquinoloneresistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact. Am J Med 2006;119(526): e19-25.
185. Kaye KS, Kanafani ZA, Dodds AE, et al. Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinoloneresistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006;50:2192-6. (Pubitemid 43807542)
186. Muto CA, Pokrywka M, Shutt K, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005;26:273-80. (Pubitemid 40445086)
187. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficileassociated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41:1254-60. (Pubitemid 41532667)
188. Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer. A trial of oral penicillin V or placebo combined with pefloxacin. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. AMA 1994;272:1183-9.
189. Gardner A, Mattiuzzi G, Faderl S, et al. Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia. J Clin Oncol 2008;26:5684-8.
190. Bow EJ, Loewen R, Cheang MS, et al. Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults. J Clin Oncol 1997;15:2254-61. (Pubitemid 27251126)
191. Blijlevens NM, Donnelly JP, de Pauw BE. Impaired gut function as risk factor for invasive candidiasis in neutropenic patients. Br J Haematol 2002;117:259-64. (Pubitemid 34451140)
192. Nucci M, Anaissie E. Revisiting the source of candidemia: skin or gut? Clin Infect Dis 2001;33:1959-67. (Pubitemid 33152388)
193. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356:335-47. (Pubitemid 46148776)
194. Kanda Y, Yamamoto R, Chizuka A, et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A metaanalysis of 16 randomized, controlled trials. Cancer 2000;89:1611-25.
195. Playford EG, Webster AC, Sorrell TC, et al. Systematic review and meta-analysis of antifungal agents for preventing fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis 2006;25:549-61. (Pubitemid 44379690)
196. Gerson SL, Talbot GH, Hurwitz S, et al. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 1984;100:345-51. (Pubitemid 14156535)
197. Portugal RD, Garnica M, Nucci M. Index to predict invasive mold infection in high-risk neutropenic patients based on the area over the neutrophil curve. J Clin Oncol 2009;27:3849-54.
198. Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006;91:1068-75. (Pubitemid 44208634)
199. de Pauw BE, Rubin RH. Empiric versus preemptive therapy in the management of febrile neutropenia in the patient being treated for hematologic malignancy. Transpl Infect Dis 2006;8:1-2.
200. DeGregorio MW, Lee WM, Linker CA, et al. Fungal infections in patients with acute leukemia. Am J Med 1982;73:543-8. (Pubitemid 12003288)
201. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-59. (Pubitemid 46148777)
202. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999;340:764-771. (Pubitemid 29114295)
203. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225-34. (Pubitemid 34438861)
204. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004;351:1391-402.
205. Wingard JR, White MH, Anaissie E, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000;31:1155-63. (Pubitemid 32295443)
206. Fleming RV, Kantarjian HM, Husni R, et al. Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma 2001;40:511-20. (Pubitemid 32303242)
207. Boogaerts M, Winston DJ, Bow EJ, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 2001;135:412-22. (Pubitemid 32845866)
208. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15. (Pubitemid 34851833)
209. Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in nonneutropenic patients: a randomised non-inferiority trial. Lancet 2005;366:1435-42. (Pubitemid 41483809)
210. Trifilio S, Singhal S, Williams S, et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2007;40:451-6. (Pubitemid 47288224)
211. Krishna G, Martinho M, Chandrasekar P, et al. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 2007;27:1627-1636. (Pubitemid 350234311)
212. Caillot D, Casasnovas O, Bernard A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997;15:139-47. (Pubitemid 27020567)
213. Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005;41:1242-50. (Pubitemid 41534660)
214. Hebart H, Klingspor L, Klingebiel T, et al. A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT. Bone Marrow Transplant 2009;43:553-61.
215. Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001;19:253-9. (Pubitemid 32063503)
216. Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007;44:373-9. (Pubitemid 46147619)
217. Kuhlman JE, Fishman EK, Siegelman SS. Invasive pulmonary aspergillosis in acute leukemia: characteristic findings on CT, the CT halo sign, the role of CT in early diagnosis. Radiology 1985;157:611-4. (Pubitemid 16232097)
218. Greene RE, Schlamm HT, Oestmann J-W, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007;44:373-9. (Pubitemid 46147619)
219. Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004;39:199-205. (Pubitemid 38971490)
220. Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005;41:654-9. (Pubitemid 41170353)
221. Senn L, Robinson JO, Schmidt S, et al. 1, 3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic-patients with acute leukemia. Clin Infect Dis 2008;46:878-85. (Pubitemid 351417190)
222. Segal BH, Almyroudis NG, Battiwalla M, et al. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis 2007;44:402-9. (Pubitemid 46147624)
223. Wheat LJ, Hackett E, Durkin M, et al. Histoplasmosis-associated cross-reactivity in the BioRad Platelia Aspergillus enzyme immunoassay. Clin Vaccine Immunol 2007;14:638-40.
224. Wheat LJ. Rapid diagnosis of invasive aspergillosis by antigen detection. Transpl Infect Dis 2003;5:158-66. (Pubitemid 41709864)
225. Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004;4:349-57. (Pubitemid 38692699)
226. Maertens J, Van Eldere J, Verhaegen J, et al. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis 2002;186:1297-306. (Pubitemid 35193008)
227. Herbrecht R, Letscher-Bru V, Oprea C, et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 2002;20:1898-906. (Pubitemid 34273282)
228. Maertens J, Verhaegen J, Lagrou K, et al. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001;97:1604-10. (Pubitemid 32217224)
229. Sulahian A, Boutboul F, Ribaud P, et al. Value of antigen detection using an enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in two adult and pediatric hematology units during a 4-year prospective study. Cancer 2001;91:311-8. (Pubitemid 32099231)
230. Pinel C, Fricker-Hidalgo H, Lebeau B, et al. Detection of circulating Aspergillus fumigatus galactomannan: value and limits of the Platelia test for diagnosing invasive aspergillosis. J Clin Microbiol 2003;41:2184-6. (Pubitemid 36576561)
231. Marr KA, Laverdiere M, Gugel A, et al. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005;40:1762-9. (Pubitemid 40799945)
232. Marr KA, Balajee SA, McLaughlin L, et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004;190:641-9. (Pubitemid 38982107)
233. Hope WW, Walsh TJ, Denning DW. Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis 2005;5:609-22. (Pubitemid 41383906)
234. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006;42:1417-727.
235. Guo YL, Chen YQ, Wang K, et al. Accuracy of bronchoalveolar lavage galactomannan in diagnosing invasive aspergillosis: a bivariate metaanalysis and systematic review. Chest 2010;138:817-24.
236. Clancy CJ, Jaber RA, Leather HL, et al. Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J Clin Microbiol 2007;45:1759-65. (Pubitemid 46933903)
237. Meersseman W, Lagrou K, Maertens J, et al. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med 2008;177:27-34.
238. Cordonnier C, Pautas C, Maury S, et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009;48:1042-51.
239. Marr KA, Leisenring W, Bow E. Empirical versus preemptive antifungal therapy for fever during neutropenia. Clin Infect Dis 2009;49:1138-9; author reply, 39-40.
240. Weisser M, Rausch C, Droll A, et al. Galactomannan does not precede major signs on a pulmonary computerized tomographic scan suggestive of invasive aspergillosis in patients with hematological malignancies. Clin Infect Dis 2005;41:1143-9. (Pubitemid 41429477)
241. Aguilar-Guisado M, Espigado I, Cordero E, et al. Empirical antifungal therapy in selected patients with persistent febrile neutropenia. Bone Marrow Transplant 2009;45:159-64.
242. de Pauw BE, Donnelly JP. Timely intervention for invasive fungal disease: should the road now lead to the laboratory instead of the pharmacy? Clin Infect Dis 2009;48:1052-4.
243. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845-51.
244. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study. J Infect Dis 1995;171:1545-52.
245. Rotstein C, Bow EJ, Laverdiere M, et al. Randomized placebocontrolled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis 1999;28:331-40.
246. Bow EJ, Laverdiere M, Lussier N, et al. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer 2002;94:3230-46. (Pubitemid 34670507)
247. Robenshtok E, Gafter-Gvili A, Goldberg E, et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol 2007;25:5471-89. (Pubitemid 350232225)
248. van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004;39:1407-16. (Pubitemid 39518200)
249. Vardakas KZ, Michalopoulos A, Falagas ME. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomisedcontrolled trials. Br J Haematol 2005;131:22-8. (Pubitemid 43899704)
250. Hachem R, Hanna H, Kontoyiannis D, et al. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 2008;112:2493-9.
251. Wingard J, Carter CL, Walsh TJ, et al. Results of a randomized, double-blind trial of fluconazole (FLU) vs. voriconazole (VORI) for the prevention of invasive fungal infections (IFI) in 600 allogenic bllod and marrow translplant (BMT) patients [abtract #163]. Blood 2007;110:55a.
252. Marks DI, Kibbler C, Pagliuca A, et al. Voriconazole (VOR) vs itraconazole (ITR) for primary prophylaxis of invasive fungal infection (IFI) in allogeneic hematopoietic cell transplant (HCT) recipients [abstract M-1249a]. In: Program and abstracts of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2009.
253. Vehreschild JJ, Bohme A, Buchheidt D, et al. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). J Infect 2007;55:445-9. (Pubitemid 47628350)
254. Mattiuzzi GN, Alvarado G, Giles FJ, et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother 2006;50:143-7. (Pubitemid 43042914)
255. Glasmacher A, Prentice A, Gorschluter M, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3, 597 patients. J Clin Oncol 2003;21:4615-26. (Pubitemid 46594036)
256. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004;103:1527-33. (Pubitemid 38168674)
257. Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for longterm antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003;138:705-13.
258. Lipp HP. Antifungal agents-clinical pharmacokinetics and drug interactions. Mycoses 2008;51(Suppl 1): 7):7-18.
259. Lebeaux D, Lanternier F, Elie C, et al. Therapeutic drug monitoring of posaconazole: a monocentric study in 54 adults. Antimicrob Agents Chemother 2009;53:5224-9.
260. Thompson GR 3rd, Rinaldi MG, Pennick G, et al. Posaconazole therapeutic drug monitoring: a reference laboratory experience. Antimicrob Agents Chemother 2009;53:2223-4.
261. Marr KA, Leisenring W, Crippa F, et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004;103:1557-9. (Pubitemid 38168678)
262. Chen S, Wu D, Sun A, et al. Itraconazole-enhanced vindesine neurotoxicity in adult acute lymphoblastic leukaemia. Am J Hematol 2007;82:942. (Pubitemid 47502706)
263. Mantadakis E, Amoiridis G, Kondi A, et al. Possible increase of the neurotoxicity of vincristine by the concurrent use of posaconazole in a young adult with leukemia. J Pediatr Hematol Oncol 2007;29:130. (Pubitemid 46213863)
264. Karp JE, Burch PA, Merz WG. An approach to intensive antileukemia therapy in patients with previous invasive aspergillosis. Am J Med 1988;85:203-6.
265. Cordonnier C, Maury S, Pautas C, et al. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant 2004;33:943-8. (Pubitemid 38660128)
266. Miyakis S, van Hal SJ, Ray J, et al. Voriconazole concentrations and outcome of invasive fungal infections. Clin Microbiol Infect 2009;16:927-33.
267. Poirier JM, Berlioz F, Isnard F, et al. Marked intra-and inter-patient variability of itraconazole steady state plasma concentrations. Therapie 1996;51:163-7. (Pubitemid 126613770)
268. Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008;46:201-11. (Pubitemid 351269158)
269. Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasisrelated death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000;96:2055-61.
270. Trifilio S, Verma A, Mehta J. Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients: heterogeneity of current clinical practice. Bone Marrow Transplant 2004;33:735-9. (Pubitemid 38499928)
271. Saral R, Burns WH, Laskin OL, et al. Acyclovir prophylaxis of herpessimplex-virus infections. N Engl J Med 1981;305:63-7.
272. Saral R, Ambinder RF, Burns WH, et al. Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study. Ann Intern Med 1983;99:773-6. (Pubitemid 14248403)
273. Boeckh M, Kim HW, Flowers ME, et al. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation-a randomized double-blind placebocontrolled study. Blood 2006;107:1800-5. (Pubitemid 43289356)
274. Limaye AP, Huang ML, Leisenring W, et al. Cytomegalovirus (CMV) DNA load in plasma for the diagnosis of CMV disease before engraftment in hematopoietic stem-cell transplant recipients. J Infect Dis 2001;183:377-82. (Pubitemid 32105596)
275. Nordoy T, Aaberge IS, Husebekk A, et al. Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae. Med Oncol 2002;19:71-8. (Pubitemid 34625928)
276. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009;9:493-504.
277. Pollyea DA, Brown JM, Horning SJ. Utility of influenza vaccination for oncology patients. J Clin Oncol 2010;28:2481-90.
278. Ortbals DW, Liebhaber H, Presant CA, et al. Influenza immunization of adult patients with malignant diseases. Ann Intern Med 1977;87:552-7. (Pubitemid 8223601)
279. Robertson JD, Nagesh K, Jowitt SN, et al. Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. Br J Cancer 2000;82:1261-5. (Pubitemid 30145342)
280. Vu D, Peck AJ, Nichols WG, et al. Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study. Clin Infect Dis 2007;45:187-93. (Pubitemid 47041009)
281. Martino R, Ramila E, Rabella N, et al. Respiratory virus infections in adults with hematologic malignancies: a prospective study. Clin Infect Dis 2003;36:1-8. (Pubitemid 36099089)
282. Peck AJ, Englund JA, Kuypers J, et al. Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection. Blood 2007;110:1681-8. (Pubitemid 47443987)
283. Weinstock DM, Eagan J, Malak SA, et al. Control of influenza A on a bone marrow transplant unit. Infect Control Hosp Epidemiol 2000;21:730-2.
284. Chemaly RF, Torres HA, Aguilera EA, et al. Neuraminidase inhibitors improve outcome of patients with leukemia and influenza: an observational study. Clin Infect Dis 2007;44:964-7. (Pubitemid 46452062)
285. Nichols WG, Guthrie KA, Corey L, et al. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis 2004;39:1300-6. (Pubitemid 39458515)
286. Nichols WG, Corey L, Gooley T, et al. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood 2001;98:573-8.
287. Small TN, Casson A, Malak SF, et al. Respiratory syncytial virus infection following hematopoietic stem cell transplantation. Bone Marrow Transpl 2002;29:321-7. (Pubitemid 34229037)
288. de Fontbrune FS, Robin M, Porcher R, et al. Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2007;45:1019-24. (Pubitemid 47580353)
289. Symeonidis N, Jakubowski A, Pierre-Louis S, et al. Invasive adenoviral infections in T-cell-depleted allogeneic hematopoietic stem cell transplantation: high mortality in the era of cidofovir. Transpl Infect Dis 2007;9:108-13. (Pubitemid 46669079)
290. Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007;25:3158-67. (Pubitemid 47218066)
291. Pinto L, Liu Z, Doan Q, et al. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin 2007;23:2283-95. (Pubitemid 350246613)
292. Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006;42:2433-53. (Pubitemid 44442936)
293. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205. (Pubitemid 46638957)
294. National Cancer Center Network (NCCN). Myeloid growth factors: NCCN practice guidelines. 2009: v. 1.2009.
295. Timmer-Bonte JN, Adang EM, Smit HJ, et al. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer. J Clin Oncol 2006;24:2991-7. (Pubitemid 46638931)
296. Timmer-Bonte JN, Adang EM, Termeer E, et al. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy. J Clin Oncol 2008;26:290-6.
297. Adams JR, Angelotta C, Bennett CL. When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective? J Clin Oncol 2006;24:2975-7. (Pubitemid 46638926)
298. Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106:2258-66. (Pubitemid 43673249)
299. Wingard JR, Elmongy M. Strategies for minimizing complications of neutropenia: prophylactic myeloid growth factors or antibiotics. Crit Rev Oncol Hematol 2009;72:144-54.
300. Lyman GH, Shayne M. Granulocyte colony-stimulating factors: finding the right indication. Curr Opin Oncol 2007;19:299-307. (Pubitemid 46883517)
301. Maher DW, Lieschke GJ, Green M, et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebocontrolled trial. Ann Intern Med 1994;121:492-501.
302. Vellenga E, Uyl-de Groot CA, de Wit R, et al. Randomized placebocontrolled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. J Clin Oncol 1996;14:619-627.
303. Garcia-Carbonero R, Mayordomo JI, Tornamira MV, et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst 2001;93:31-8. (Pubitemid 32060887)
304. Clark OA, Lyman GH, Castro AA, et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 2005;23:4198-214. (Pubitemid 46211326)
305. Raad I, Hanna HA, Alakech B, et al. Differential time to positivity: a useful method for diagnosing catheter-related bloodstream infections. Ann Intern Med 2004;140:18-25.
306. Maki DG, Kluger DM, Crnich CJ. The risk of bloodstream infection in adults with different intravascular devices: a systematic review of 200 published prospective studies. Mayo Clin Proc 2006;81:1159-71. (Pubitemid 44316281)
307. Raad I, Costerton W, Sabharwal U, et al. Ultrastructural analysis of indwelling vascular catheters: a quantitative relationship between luminal colonization and duration of placement. J Infect Dis 1993;168:400-7. (Pubitemid 23210618)
308. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009;49:1-45.
309. Seifert H, Cornely O, Seggewiss K, et al. Bloodstream infection in neutropenic cancer patients related to short-term nontunnelled catheters determined by quantitative blood cultures, differential time to positivity, and molecular epidemiological typing with pulsed-field gel electrophoresis. J Clin Microbiol 2003;41:118-23. (Pubitemid 36098564)
310. Chatzinikolaou I, Hanna H, Hachem R, et al. Differential quantitative blood cultures for the diagnosis of catheter-related bloodstream infections associated with short-and long-term catheters: a prospective study. Diagn Microbiol Infect Dis 2004;50:167-72. (Pubitemid 39487289)
311. Douard MC, Clementi E, Arlet G, et al. Negative catheter-tip culture and diagnosis of catheter-related bacteremia. Nutrition 1994;10:397-404. (Pubitemid 24292614)
312. Capdevila JA, Planes AM, Palomar M, et al. Value of differential quantitative blood cultures in the diagnosis of catheter-related sepsis. Eur J Clin Microbiol Infect Dis 1992;11:403-7.
313. Douard MC, Arlet G, Longuet P, et al. Diagnosis of venous access port-related infections. Clin Infect Dis 1999;29:1197-202. (Pubitemid 30265639)
314. Flynn PM, Shenep JL, Barrett FF. Differential quantitation with a commercial blood culture tube for diagnosis of catheter-related infection. J Clin Microbiol 1988;26:1045-6.
315. Raucher HS, Hyatt AC, Barzilai A, et al. Quantitative blood cultures in the evaluation of septicemia in children with Broviac catheters. J Pediatr 1984;104:29-33. (Pubitemid 14178456)
316. Safdar N, Fine JP, Maki DG. Meta-analysis: methods for diagnosing intravascular device-related bloodstream infection. Ann Intern Med 2005;142:451-66. (Pubitemid 40365432)
317. Blot F, Schmidt E, Nitenberg G, et al. Earlier positivity of centralvenous-versus peripheral-blood cultures is highly predictive of catheter-related sepsis. J Clin Microbiol 1998;36:105-9. (Pubitemid 28047442)
318. Blot F, Nitenberg G, Chachaty E, et al. Diagnosis of catheter-related bacteraemia: a prospective comparison of the time to positivity of hub-blood versus peripheral-blood cultures. Lancet 1999;354:1071-7. (Pubitemid 29452819)
319. Fowler VG Jr., Sanders LL, Sexton DJ, et al. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clin Infect Dis 1998;27:478-86. (Pubitemid 28421994)
320. Dugdale DC, Ramsey PG. Staphylococcus aureus bacteremia in patients with Hickman catheters. Am J Med 1990;89:137-41. (Pubitemid 20254436)
321. Hanna H, Afif C, Alakech B, et al. Central venous catheter-related bacteremia due to gram-negative bacilli: significance of catheter removal in preventing relapse. Infect Control Hosp Epidemiol 2004;25:646-9. (Pubitemid 39095046)
322. Nguyen MH, Peacock JE Jr., Tanner DC, et al. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med 1995;155:2429-35.
323. Raad I, Hanna H, Boktour M, et al. Management of central venous catheters in patients with cancer and candidemia. Clin Infect Dis 2004;38:1119-27. (Pubitemid 38951258)
324. Benoit JL, Carandang G, Sitrin M, et al. Intraluminal antibiotic treatment of central venous catheter infections in patients receiving parenteral nutrition at home. Clin Infect Dis 1995;21:1286-8.
325. Johnson DC, Johnson FL, Goldman S. Preliminary results treating persistent central venous catheter infections with the antibiotic lock technique in pediatric patients. Pediatr Infect Dis J 1994;13:930-1. (Pubitemid 24322793)
326. Krzywda EA, Andris DA, Edmiston CE Jr., et al. Treatment of Hickman catheter sepsis using antibiotic lock technique. Infect Control Hosp Epidemiol 1995;16:596-8.
327. Messing B, Peitra-Cohen S, Debure A, et al. Antibiotic-lock technique: a new approach to optimal therapy for catheter-related sepsis in home-parenteral nutrition patients. JPEN J Parenter Enteral Nutr 1988;12:185-9. (Pubitemid 18087294)
328. Raad I, Buzaid A, Rhyne J, et al. Minocycline and ethylenediaminetetraacetate for the prevention of recurrent vascular catheter infections. Clin Infect Dis 1997;25:149-51. (Pubitemid 27293088)
329. Ghanem GA, Boktour M, Warneke C, et al. Catheter-related Staphylococcus aureus bacteremia in cancer patients: high rate of complications with therapeutic implications. Medicine (Baltimore) 2007;86:54-60. (Pubitemid 46104920)
330. Raad II, Hohn DC, Gilbreath BJ, et al. Prevention of central venous catheter-related infections by using maximal sterile barrier precautions during insertion. Infect Control Hosp Epidemiol 1994;15:231-8.
331. Boyce JM, Pittet D. Guideline for hand hygiene in health-care settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America. MMWR Recomm Rep 2002;51:1-45; quiz, CE1-4.
332. Siegel JD, Rhinehart E, Jackson M, et al. 2007 Guideline for isolation precautions: preventing transmission of infectious agents in health care settings. Am J Infect Control 2007;35: S65-164. (Pubitemid 350213178)
333. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 2000;49:1-125, CE1-7.
334. Immunization of health-care workers: recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 1997;46:1-42.
335. Yokoe DS, Mermel LA, Anderson DJ, et al. A compendium of strategies to prevent healthcare-associated infections in acute care hospitals. Infect Control Hosp Epidemiol 2008;29(Suppl 1): S12-21.
336. U. S. Food and Drug Administration. (2009). "Information for Healthcare Professionals: Cefepime (marketed as Maxipime)." Retrieved June 21, 2009, from http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm167254.htm.
337. National Comprehensive Cancer Network (NCCN). (2009). "Prevention and Treatment of Cancer-Related Infections v. 2." Retrieved August, 2009, from (http://www.nccn.org/professionals/physician-gls/f-guidelines. asp#supportive).